%0 Journal Article
%T How should anti-hypertensive medications be adjusted before screening for primary aldosteronism?
%A Lu JY
%A Chang YY
%A Lee TW
%A Wu MH
%A Chen ZW
%A Huang YT
%A Lai TS
%A Er LK
%A Lin YH
%A Wu VC
%A Cheng HM
%A Kao HL
%A Jia-Yin Hou C
%A Wu KD
%A Chen ST
%A Liu FH
%J J Formos Med Assoc
%V 123
%N 0
%D 2024 Mar 6
%M 37291044
%F 3.871
%R 10.1016/j.jfma.2023.05.021
%X Anti-hypertensive medications may affect plasma renin activity and/or plasma aldosterone concentration, misleading the interpretation of the aldosterone-to-renin ratio when screening for primary aldosteronism. The Task Force of Taiwan PA recommends that, when necessary, using α-adrenergic receptor blocking agents, centrally acting α-adrenergic agonists, and/or non-dihydropyridine calcium channel blockers should be considered to control blood pressure before screening for PA. We recommend temporarily holding β-adrenergic receptor blocking agents, mineralocorticoid receptor antagonists, dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and all diuretics before screening for PA. Further large-scale randomized controlled studies are required to confirm the recommendations.